Actively Recruiting

Phase Not Applicable
Age: 8Years +
All Genders
Healthy Volunteers
NCT04187599

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)

Led by CooperVision International Limited (CVIL) · Updated on 2019-12-05

250

Participants Needed

4

Research Sites

70 weeks

Total Duration

On this page

Sponsors

C

CooperVision International Limited (CVIL)

Lead Sponsor

T

TigerMed

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main objective of this post market clinical study is to evaluate the effectiveness and safety of the Paragon CRT®100 Contact Lens.

CONDITIONS

Official Title

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)

Who Can Participate

Age: 8Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient contact lens refraction must be within the study lens parameters: spherical power between -4.00D and cylinder power within 1.50D
  • Willing to comply with the lens wear and visit schedule
  • Willing to participate and have signed the informed consent form
Not Eligible

You will not qualify if you...

  • Age under 8 years old
  • Any ocular abnormalities, previous corneal surgery, history of eye trauma, active corneal infections, or corneal curvature outside 40.00D to 46.00D
  • Best corrected visual acuity less than 1.0D
  • Pregnant, lactating, or near pregnancy
  • Acute or subacute inflammation or infection of the eye's anterior segment
  • Any eye disease, injury, or abnormality affecting the cornea, conjunctiva, or eyelids (e.g., dacryocystitis, conjunctivitis, blepharitis, glaucoma)
  • Severe tear insufficiency (TBUT 3s)
  • Allergy to any solution ingredient such as mercury or thimerosal
  • Any active bacterial, fungal, or viral corneal infection
  • Manifested strabismus
  • Abnormal intra-ocular pressure
  • Systemic diseases causing low immunity or affecting corneal reshaping (e.g., sinusitis, diabetes, Down syndrome, rheumatoid arthritis, mental illness)
  • Use of medications causing dry eye or affecting vision and corneal curvature
  • Any contraindication or unsuitability for OrthoK lens wear based on examination
  • Participation in a pharmaceutical clinical study within 3 months or other medical device study within 30 days before screening
  • Only one eye meets inclusion criteria
  • History of any eye surgery
  • Unable to follow investigator instructions
  • Any other condition deemed unsuitable by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Changsha Aier Eye Hospital

Shanghai, China

Actively Recruiting

2

Eye & ENT Hospital of Fudan University

Shanghai, China

Actively Recruiting

3

Tianjin Eye Hospital

Tianjin, China

Actively Recruiting

4

The Affiliated Eye Hospital of Wenzhou Medical University

Wenzhou, China

Actively Recruiting

Loading map...

Research Team

J

Jose Vega, OD, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D) | DecenTrialz